



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2011

(Rs. in Lacs except for share data)

PARTICULARS	For the Quarter Ended 31st Mar 2011	For the Quarter Ended 31st Mar 2010	For the Year ended 31st Mar 2011	For the Year ended 31st Mar 2010	Consolidated For the Year ended 31st Mar 2011	Consolidated For the Year ended 31st Mar 2010
(Gross) Sales / Income from operations	15,102	13,428	52,301	49,695	52,762	50,408
Less : Excise Duty & Sales Tax	767	736	2,659	2,553	2,647	2,557
1. (a) (Net) Sales / Income from operations	14,335	12,692	49,642	47,142	50,105	47,850
(b) Other Operating Income	-	-	-	-	-	-
2. Expenditure						
(a). (Increase) / Decrease in stock in trade	352	400	(1,618)	376	(1,870)	316
(b). Consumption of raw materials.	7,985	5,932	27,300	23,179	27,666	23,177
(c). Purchase of Traded Goods	1,648	2,258	8,421	8,202	7,833	7,732
(d). Employees cost	432	351	1,646	1,362	1,993	1,477
(e). Depreciation	417	348	1,548	1,352	1,911	1,703
(f). Other expenditure	2,158	1,901	7,858	6,859	7,985	7,108
(g). Total Expenditure	13,193	11,190	45,155	41,330	45,318	41,513
3. Profit from Operations before Other Income, Interest and exceptional items	1,142	1,501	4,487	5,811	4,787	6,337
4. Other Income	1	11	8	45	16	63
5. Profit before Interest & Exceptional items	1,143	1,512	4,495	5,856	4,803	6,400
6. Interest	409	331	1,348	1,474	1,492	1,660
7. Profit after Interest but before Exceptional items	734	1,181	3,147	4,382	3,311	4,740
8. Exceptional items	-	-	-	-	-	-
9. Profit from Ordinary Activities before Tax	734	1,181	3,147	4,382	3,311	4,740
10. Tax Expenses (Includes)	105	458	900	1,772	961	1,896
Provision for Taxation	64	391	650	1,502	792	1,642
Provision for Deferred Taxation	41	68	250	270	169	254
11. Net profit from ordinary Activities after Tax	629	723	2,247	2,610	2,350	2,844
12. Extraordinary item (net of tax expenses)	-	-	-	-	-	-
13. Net Profit for the period	629	723	2,247	2,610	2,350	2,844
Less						
a) Minority Interest	-	-	-	-	-	36
b) Adjustment on Consolidation	-	-	-	-	-	3
c) Share of Profit/(Loss) in Associate	-	-	-	-	9	19
Profit After Consolidation adjustment	629	723	2,247	2,610	2,371	2,823
14. Paid-up Equity Share Capital of Rs.10/- each.	1,211	1,211	1,211	1,211	1,211	1,211
15. Reserves & Surplus (excluding revaluation reserves)	-	-	14,441	12,898	16,105	13,434
16. Basic EPS (in Rs.)	5.19	5.97	18.56	22.08	19.58	23.88
17. Public Shareholding						
Number of Shares	5569613	6051226	5569613	6051226	5569613	6051226
Percentage of Total Shareholding	46.00	49.97	46.00	49.97	46.00	49.97
18. Promoters & Promoter Group Shareholding**						
a) Pledged/Encumbered						
- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a percentage of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a percentage of total sharecapital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered						
- Number of Shares	6538937	6057324	6538937	6057324	6538937	6057324
- Percentage of shares (as a percentage of total shareholding of promoter and promoter group)	100	100	100	100	100	100
- Percentage of shares (as a percentage of total sharecapital of the Company)	54.00	50.03	54.00	50.03	54.00	50.03

Notes :

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 28th May 2011.
- The Board of Directors has recommended Final Dividend of Rs.2.5/- per share (25%) on 1,21,08,550 Equity shares of Rs.10/- each fully paid-up for the Financial year 2010-11
- Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 "Segment Reporting" is not attracted.
- Figures of the previous periods have been regrouped and rearranged wherever necessary.
- Number of Investors complaints (i) pending at the beginning of quarter 2 (ii) received during the quarter : 1 (iii) redressed : 3
(iv) pending at the end of the quarter : 0.

For and on behalf of the Board
FOR AARTI DRUGS LIMITED

Harsh M. Savia
(Jt. Managing Director)

Place : Mumbai
Date : 25th May, 2011

Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist. Thane - 401 506. (MH)



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2011

(₹ In Lacs)

Particulars	As at 31st Mar-11 (Audited)	As at 31st Mar-10 (Audited)	Consolidated As at 31st, Mar-11 (Audited)	Consolidated As at 31st, Mar-10 (Audited)
SHAREHOLDERS FUNDS				
(a) Capital	1,211	1,211	1,211	1,211
(b) Reserves and Surplus	14,441	12,898	15,105	13,434
LOAN FUNDS	24,749	17,764	26,749	18,883
Deferred Tax Liability	2,230	1,980	2,271	2,103
Minority Interest	-	-	-	486
TOTAL	42,631	33,853	45,336	36,117
FIXED ASSETS	22,421	18,354	24,784	20,820
CAPITAL WIP	1,037	340	1,037	340
INVESTMENTS	2,461	2,138	528	174
CURRENT ASSETS, LOANS AND ADVANCES	25,669	20,032	25,985	20,573
(a) Inventories	8,316	5,858	9,183	6,441
(b) Sundry Debtors	12,583	11,845	12,134	11,587
(c) Cash and Bank balances	359	365	527	852
(d) Other current assets	241	196	289	233
(e) Loans and Advances	4,170	1,768	3,851	1,460
Less : Current Liabilities and Provisions				
(a) Liabilities	8,655	6,393	6,707	5,186
(b) Provisions	303	617	291	605
NET WORKING CAPITAL	16,711	13,022	18,986	14,782
TOTAL	42,631	33,853	45,336	36,117

For and on behalf of the Board
FOR AARTIDRUGS LIMITED

Harshit M Savia
(Jt. Managing Director)

Place : Mumbai
Date : 25th May, 2011

Regd. Office : Plot No. N-198, MIDC, Tarapur, Tal-Palghar, Dist. Thane - 401 506. (MH)